U.S. Other Utilities Stock News

NYSE:DOCS
NYSE:DOCSHealthcare Services

Does Doximity’s (DOCS) Scale With Physicians and Cash Flow Redefine Its Healthcare Tech Moat?

Doximity recently highlighted that its platform now reaches over 80% of U.S. physicians and has delivered annual revenue growth of about 29.3% over the past five years, while generating strong free cash flow that can be used for investment or capital returns. This combination of broad physician adoption and substantial cash generation underscores Doximity’s position as a core digital tool for clinicians and a financially flexible business within healthcare technology. Next, we’ll examine how...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback

Recent Stock Performance and Business Context Travere Therapeutics (TVTX) has drawn investor attention after recent trading that leaves the shares about 8.5% lower over the past month and roughly 27.7% lower over the past 3 months. The company focuses on therapies for rare kidney and metabolic diseases, generates US$490.7m in revenue, and currently reports a net loss of US$50.3m, which keeps profitability and funding on many investors’ radar. See our latest analysis for Travere...
NYSE:NOW
NYSE:NOWSoftware

ServiceNow’s Armis Deal Recasts AI Platform Around Security And Capital Choices

ServiceNow (NYSE:NOW) announced a record $7.75b acquisition of cybersecurity firm Armis, expanding its AI powered platform deeper into security. The deal marks the largest acquisition in ServiceNow's history and follows recent alliances focused on AI agent resilience and security, including partnerships with Cohesity and Zenity. This move raises fresh questions around capital allocation, risk management, and how security will sit alongside ServiceNow's core workflow and automation...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

United Therapeutics Tyvaso IPF Success Adds New Layer To Valuation Story

United Therapeutics reported positive phase 3 results from its TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF). The trial met its primary efficacy endpoint and showed significant benefits over placebo with a favorable safety profile. The company plans to seek a supplemental FDA approval to add IPF to the Tyvaso label, supported by integrated data from TETON-1 and TETON-2. For investors watching United Therapeutics, ticker NasdaqGS:UTHR, this news arrives with the...
NYSE:BEN
NYSE:BENCapital Markets

Is Franklin Resources (BEN) Now Attractive After Recent Pullback And One Year Rebound?

If you are wondering whether Franklin Resources at around US$22.75 is offering good value or potential overpayment, the recent share price path gives you a useful starting point. The stock has seen a 4.8% decline over the last week and a 14.3% decline over the last month, yet it still shows a 23.1% return over the past year, which can change how investors think about both risk and opportunity. Across the market, investors have been closely watching asset managers as sentiment around capital...
NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

Strategy Bitcoin Buying Pause Raises Questions On Valuation And Risk Mix

Strategy, traded as NasdaqGS:MSTR, appears to have paused its weekly Bitcoin purchases after a 13 week streak. No recent Bitcoin accumulation has been reported or publicized by Executive Chairman Michael Saylor. The pause breaks an established buying pattern that had become central to the company’s Bitcoin treasury approach. This shift comes alongside recent changes in preferred stock funding used to support prior Bitcoin acquisitions. For readers following NasdaqGS:MSTR, the company is...
NasdaqGS:BATR.K
NasdaqGS:BATR.KEntertainment

Is Atlanta Braves Holdings (BATR.K) Pricing In Too Much Future Growth After Recent Pullback

Wondering if Atlanta Braves Holdings at around US$41.53 is offering good value or just a fan premium? This breakdown is designed to help you see what the current price really represents. The stock has seen a 1% decline over the last 7 days and a 5% decline over the last 30 days, while still showing returns of 4.2% year to date, 3.8% over 1 year, 23.2% over 3 years and 43.2% over 5 years. Recent coverage has focused on the company as a way to gain exposure to a well known sports franchise...
NYSE:NBHC
NYSE:NBHCBanks

A Look At National Bank Holdings (NBHC) Valuation After Recent Share Price Softness

Why National Bank Holdings is on investors’ radar National Bank Holdings (NBHC) has been drawing attention after a recent period of mixed share performance, with a 1 day decline of 1.6% and a month return of 5.1%. Against that backdrop, investors are weighing the bank’s current valuation against its reported US$398.3m in revenue and US$108.7m in net income, along with multi year total return figures that extend up to the past 5 years. See our latest analysis for National Bank Holdings. At a...
NYSE:PINS
NYSE:PINSInteractive Media and Services

Does Pinterest (PINS) Elliott-Backed Buyback Clarify Its AI Monetization Story or Complicate It?

Pinterest recently received a US$1.00 billion investment from affiliates of Elliott Investment Management and used the funds to launch a US$1.00 billion accelerated share repurchase under a broader US$3.50 billion board-approved program, underscoring its focus on capital returns. This move highlights Pinterest’s strong free cash flow profile and signals management’s confidence in the platform’s ability to support shareholder-focused capital allocation. We’ll now examine how this large...
NYSE:LAZ
NYSE:LAZCapital Markets

Lazard Insider Reshapes Stake While Retaining Long Term Exposure

Christopher Hogbin, CEO of Asset Management at Lazard, recently exercised a sizable block of stock options. Following the exercise, he sold a significant portion of common shares, reducing his direct shareholdings. Hogbin still holds a large position in Lazard through outstanding restricted stock units, keeping meaningful exposure to NYSE:LAZ. Lazard, traded on the NYSE under ticker NYSE:LAZ, last closed at $39.11. The share price reflects a 22.7% decline over the past 30 days and a 21.4%...
NYSE:CWAN
NYSE:CWANSoftware

Is Clearwater Analytics Holdings (CWAN) Fairly Priced After Recent 3-Year 48.6% Share Price Gain

Wondering if Clearwater Analytics Holdings at around US$23.49 is offering good value right now, or if the price already reflects most of the upside you care about. The stock has been relatively steady in the near term, with a 0.9% return over the last 7 days and 0.4% over the last 30 days, while year to date it shows a 2.6% decline and the 1 year return sits at a 12.4% decline, compared with a 48.6% gain over 3 years. Recent coverage has focused on Clearwater Analytics Holdings as a listed...
NYSE:WAL
NYSE:WALBanks

Western Alliance Bancorporation (WAL) Valuation Check After New Fiserv Agent Bank Partnership Announcement

Why the new Fiserv partnership matters for Western Alliance Bancorporation (WAL) Western Alliance Bancorporation (WAL) is back in focus after Fiserv announced an agent bank partnership that brings its Clover payments and business management tools directly to Western Alliance Bank’s commercial clients. The arrangement, described by Fiserv as its largest agent bank partnership by asset size, expands Western Alliance’s access to merchant technology for businesses ranging from small firms to...
NYSE:JBS
NYSE:JBSFood

Assessing JBS (NYSE:JBS) Valuation After Recent Share Price Momentum And Earnings Stability

With no single headline event driving attention today, JBS (NYSE:JBS) is drawing interest as investors look at its recent share moves and its sizeable global meat processing footprint across beef, pork, poultry, and prepared foods. See our latest analysis for JBS. JBS’s recent 7 day share price return of 13.01% and 90 day share price return of 17.53%, with the stock now at $17.03, suggest momentum has picked up after a quieter 30 day share price return of 0.83%. If the JBS move has you...
NYSE:HE
NYSE:HEElectric Utilities

Hawaiian Electric Settlement Eases Legal Pressure But Leaves Court Risks

Hawaiian Electric Industries (NYSE:HE) has agreed to a $100 million settlement to resolve significant stockholder derivative lawsuits. The payment will be funded by insurers and also partially settles a related securities class action. The agreement is subject to final court approval, with upcoming hearings expected to clarify the remaining legal process. For shareholders watching NYSE:HE at a current share price of $14.67, this settlement addresses a key source of legal uncertainty. The...
NYSE:UNP
NYSE:UNPTransportation

Is Union Pacific (UNP) Offering Value After Its Recent 9.9% Share Price Pullback

Curious if Union Pacific at around US$238.79 is offering fair value or a margin of safety right now? This article walks through the key numbers that matter for you. The stock has seen mixed returns recently, with a 0.2% move over the last 7 days, a 9.9% decline over 30 days, gains of 3.0% year to date and 3.5% over the last year, and gains of 28.2% over 3 years and 19.6% over 5 years. Recent coverage of Union Pacific has focused on its role as a major U.S. railroad operator and how broader...
NasdaqGS:XEL
NasdaqGS:XELElectric Utilities

Xcel Energy Dam Safety Filings And What They May Mean For Investors

Xcel Energy (NasdaqGS:XEL) has filed new regulatory materials with the Federal Energy Regulatory Commission focused on dam safety and compliance. The company’s recent correspondence covers dam stability, embankment integrity, and landslide monitoring at its hydro-related facilities. These filings outline ongoing safety measures and responses to federal oversight of critical infrastructure. Xcel Energy, a regulated electric and natural gas utility, depends on reliable generation and...
NasdaqGS:SFD
NasdaqGS:SFDFood

Is It Too Late To Consider Smithfield Foods (SFD) After A 36.9% One Year Rally?

For readers wondering whether Smithfield Foods at US$26.69 still offers value, or if the easy gains are already behind it, this article breaks down what the current price might be implying. The stock has returned 13.7% over the past week, 7.3% over the last month, 20.5% year to date, and 36.9% over the past year, which naturally raises questions about how expectations and risk are now being priced in. Recent coverage around Smithfield Foods has focused on its positioning within the food...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Is It Too Late To Consider Viavi Solutions (VIAV) After A 210% One Year Surge?

If you are wondering whether Viavi Solutions at US$34.64 is still attractively priced after a big run, the key question is what that price actually reflects about the business. The stock has delivered returns of 3.1% over the past week, 16.6% over the past month, 90.9% year to date and 209.6% over the last year, with a 225.3% return over three years and 114.0% over five years, which puts recent valuation questions front and center. Recent coverage has focused on Viavi Solutions as a...
NYSE:DUK
NYSE:DUKElectric Utilities

How South Carolina’s New 1,365 MW Gas Plant Approval Could Impact Duke Energy (DUK) Investors

The Public Service Commission of South Carolina has approved Duke Energy’s plan to build an approximately 1,365 MW high-efficiency natural gas plant in Anderson County, with construction targeted to start in 2027 and operations by early 2031, following an extensive public review and community engagement process. This facility, expected to support more than 2,200 jobs annually during construction and deliver an estimated US$84 million in yearly statewide economic impact once operational, also...
NasdaqCM:PVLA
NasdaqCM:PVLABiotechs

Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus

Palvella Therapeutics (NasdaqCM:PVLA) has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. McDonough has extensive experience launching and commercializing therapies for rare skin diseases, including work on VYJUVEK®. The appointment is intended to support Palvella’s commercial readiness as QTORIN™ rapamycin advances through late-stage trials. For investors watching rare disease drug developers, Palvella Therapeutics sits at the intersection of...
NYSE:BBY
NYSE:BBYSpecialty Retail

Best Buy’s Dividend Hike And Earnings Beat Could Be A Game Changer For Best Buy (BBY)

In the past week, Best Buy reported quarterly results showing adjusted EPS of US$2.61, up 1.2% year over year, alongside a 0.8% decline in comparable sales and slightly softer-than-expected revenue, while also announcing a 1% increase in its quarterly dividend to US$0.96 per share. Management’s decision to raise the dividend and emphasize scalable profit drivers such as its digital Marketplace and Best Buy Ads highlights a focus on recurring, higher-margin revenue streams even as top-line...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Did Strong Q3 Results and Heavy Buybacks Just Reframe Paychex's (PAYX) Profitability Story?

In late March 2026, Paychex reported third-quarter revenue of US$1,808.9 million and net income of US$560.3 million, alongside updates on completing two share repurchase authorizations totaling US$400 million and US$352.22 million, and highlighted its cybersecurity focus ahead of an RSA Conference presentation. While revenue and quarterly earnings per share increased year over year, nine-month net income and EPS were slightly lower, underscoring that growth in sales has not yet translated...
NasdaqGS:CALM
NasdaqGS:CALMFood

Reassessing Cal-Maine Foods (CALM) After Recent Share Price Weakness

If you are wondering whether Cal-Maine Foods at around US$77.12 is pricing in too much optimism or leaving some value on the table, a closer look at its valuation can help frame that question. The share price is near US$77.12 after a 0.1% move over the last 7 days, with an 11.5% decline over 30 days, a 1.7% decline year to date, a 7.8% decline over 1 year, but a 53.8% gain over 3 years and a 159.0% gain over 5 years. Recent coverage has focused on Cal-Maine Foods as a key player in the US...
NasdaqGS:CDW
NasdaqGS:CDWElectronic

A Look At CDW (CDW) Valuation After Recent Share Price Weakness

CDW stock performance context CDW (CDW) has drawn attention after a period where the share price shows a 2.5% decline over the past day and negative returns over the week, month, past 3 months, year to date, and past year. See our latest analysis for CDW. At a share price of $118.17, CDW’s recent 1 day share price decline of 2.5% sits within a broader period of weaker momentum, with a 1 year total shareholder return of 25.0% in the red. This may reflect cooler sentiment around its risk and...